




#4
B
Attorney Docket P1093P1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Manuel Baca et al. Serial No.: 09/723,752 Filed: November 27, 2000 For: ANTI-VEGF ANTIBODIES	Group Art Unit: To Be Assigned Examiner: To Be Assigned CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on June 26, 2001  Eileen Ly
---	---

PRELIMINARY AMENDMENT

Box Missing Parts
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to Examination, Applicants respectfully request entry of the following Preliminary Amendment.

In the Claims:

✓ Please cancel claims 39-42.

Please add new claims 43-59 as follows:

- Sub 107*
B1
43. (New) A method for inhibiting VEGF-induced angiogenesis in a subject, comprising administering to said subject an effective amount of a humanized anti-VEGF antibody which binds human VEGF with a K_d value of no more than about $1 \times 10^{-8}M$.
44. (New) The method of claim 43, wherein said humanized anti-VEGF antibody which binds human VEGF with a K_d value of no more than about $1 \times 10^{-9}M$.
45. (New) The method of claim 43, wherein said subject has a tumor.
46. (New) The method of claim 45, wherein 5mg/kg of said humanized antibody inhibits at least about 50% of tumor growth in an A673 *in vivo* tumor model.
- Sub C2*
47. (New) The method of claim 43, said humanized anti-VEGF antibody having a heavy chain variable domain comprising the following hypervariable region amino acid sequences: CDRH1 (GYX₁FTX₂YGMN, wherein X₁ is T or D and X₂ is N or H; SEQ ID NO: 128), CDRH2